Severe food allergy and anaphylaxis : treatment, risk assessment and risk reduction

dc.contributor.authorRisenga, Samuel Malamulele
dc.contributor.authorKriel, M.
dc.contributor.authorKarabus, S.
dc.contributor.authorManjra, Ahmed I.
dc.contributor.authorGray, Claudia L.
dc.contributor.authorGoddard, E.
dc.contributor.authorLang, A.C.
dc.contributor.authorTerblanche, Alta J.
dc.contributor.authorVan der Spuy, D.A.
dc.contributor.authorLevin, M.E.
dc.date.accessioned2015-03-03T05:59:42Z
dc.date.available2015-03-03T05:59:42Z
dc.date.issued2015-01
dc.description.abstractAn anaphylactic reaction may be fatal if not recognised and managed appropriately with rapid treatment. Key steps in the management of anaphylaxis include eliminating additional exposure to the allergen, basic life-support measures and prompt intramuscular administration of adrenaline 0.01 mg/kg (maximum 0.5 mL). Adjunctive measures include nebulised bronchodilators for lower-airway obstruction, nebulised adrenaline for stridor, antihistamines and corticosteroids. Patients with an anaphylactic reaction should be admitted to a medical facility so that possible biphasic reactions may be observed and risk-reduction strategies initiated or reviewed after recovery from the acute episode. Factors associated with increased risk of severe reactions include co-existing asthma (and poor asthma control), previous severe reactions, delayed administration of adrenaline, adolescents and young adults, reaction to trace amounts of foods, use of non-selective β-blockers and patients who live far from medical care. Risk-reduction measures include providing education with regard to food allergy and a written emergency treatment plan on allergen avoidance, early symptom recognition and appropriate emergency treatment. Risk assessment allows stratification with provision of injectable adrenaline (preferably via an auto-injector) if necessary. Patients with ambulatory adrenaline should be provided with written instructions regarding the indications for and method of administration of this drug and trained in its administration. Patients and their caregivers should be instructed about how to avoid foods to which the former are allergic and provided with alternatives. Permission must be given to inform all relevant caregivers of the diagnosis of food allergy. The patient must always wear a MedicAlert necklace or bracelet and be encouraged to join an appropriate patient support organisation.en_ZA
dc.description.librarianhb2015en_ZA
dc.description.urihttp://www.samj.org.zaen_ZA
dc.identifier.citationRisenga, SM, Kriel, M, Karabus, S, Manjra, AI, Gray, CL, Goddard, E, Lang, AC, Terblanche, AJ, Van der Spuy, DA & Levin, ME 2015, 'Severe food allergy and anaphylaxis : treatment, risk assessment and risk reduction', South African Medical Journal , vol. 105, no. 1, pp. 72-73.en_ZA
dc.identifier.issn0256-9574 (print)
dc.identifier.issn2078-5135 (online)
dc.identifier.issn10.7196/SAMJ.9099
dc.identifier.urihttp://hdl.handle.net/2263/43838
dc.language.isoenen_ZA
dc.publisherHealth and Medical Publishing Groupen_ZA
dc.rights© 2015 Health & Medical Publishing Group. This work is licensed under a Creative Commons Attribution-NonCommercial Works License (CC BY-NC 3.0).en_ZA
dc.subjectSevere food allergyen_ZA
dc.subjectAnaphylaxisen_ZA
dc.subjectTreatmenten_ZA
dc.subjectRisk assessmenten_ZA
dc.subjectRisk reductionen_ZA
dc.subjectAllergic reactions to foodsen_ZA
dc.titleSevere food allergy and anaphylaxis : treatment, risk assessment and risk reductionen_ZA
dc.typeArticleen_ZA

Files

Original bundle

Now showing 1 - 1 of 1
Loading...
Thumbnail Image
Name:
Risenga_Severe_2015.pdf
Size:
100 KB
Format:
Adobe Portable Document Format
Description:
Article

License bundle

Now showing 1 - 1 of 1
Loading...
Thumbnail Image
Name:
license.txt
Size:
1.71 KB
Format:
Item-specific license agreed upon to submission
Description: